It is demonstrated that adapting bacteria to the unique characteristics of the tumor metabolic microenvironment can drive the development of safer and more effective chassis for next‑generation bacterial cancer therapies.
Abstract
Despite decades of investigation, the fundamental molecular and cellular principles that enable bacteria to thrive within the tumor microenvironment have yet to be defined. Here, through a genome‑wide functional screen, we identify the bacterial genes and pathways that govern intratumoral fitness. Targeted deletion of nonglucose phosphotransferase systems to align bacterial metabolic preference with tumor metabolite availability promotes bacterial intratumoral fitness. Integrating multiple metabolic adaptations into a single tumor‑avid Escherichia coli strain (Ec‑TA) results in increased tumor colonization, not only after intratumoral delivery but also after intravenous delivery, leading to increased anti‑tumor efficacy when using Ec‑TA engineered to deliver an encoded immunostimulatory payload. Furthermore, Ec‑TA displaces wild‑type bacteria from pre‑colonized tumors when administered systemically, underscoring its potential for locally delivering therapeutics in the presence of resident tumor microbes. These data demonstrate that adapting bacteria to the unique characteristics of the tumor metabolic microenvironment can drive the development of safer and more effective chassis for next‑generation bacterial cancer therapies.
The tumor microenvironment (TME) comprises malignant, stromal, immune, and microbial components. Spatial imaging and molecular profiling have identified intracellular bacteria or bacterial signals in selected tumors, although localization, viability, and functional significance vary across tumor types and experimenta...
Xiao-Yan Chen, Jun-Feng Zhang, Jiu-Hu Li et al.· Microbial Cell Factories· 0 citations
The tumour-trophic Salmonella enterica serovar Typhimurium strain SL7207 has previously been demonstrated to successfully deliver shRNA targeting the oncogene c-Myc in murine models (Williams et al., 2024). This project extends the utility of SL7207 as a bacterial delivery platform for therapeutic RNA interference, foc...
Clinical development will require reproducible good manufacturing practice, control of endotoxin and host-cell contaminants, product stability, resistance and immune-neutralization monitoring, environmental-shedding assessment, and regulatory strategies for genetically modified, dynamically updated, and multi-component...
U. Saeed, Z. Piracha· Frontiers in Microbiology· 0 citations
This study reports the first systematic screening of strong constitutive anaerobic promoters in the probiotic Escherichia coli Nissle 1917 (EcN), establishing a precision delivery framework for potent yet highly toxic anticancer agents, facilitating the development of bacterial biotherapeutics.
Tian-Qi Cui, Guang-Le Yu, Chan-Juan Jiang et al.· Journal of Controlled Releas...· 0 citations
This review examines the genetic design principles and liabilities of bacteria-based therapeutics, approaches used to produce clinical and near-clinical candidates, and the emergence of programmed bacteria delivering complete gene editing systems to therapeutically relevant cells.
Ashley B. Williams, Thomas M. Groseclose, Sara A. M. Holec et al.· Genetics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.